Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Female Condom

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,749 result(s) found for: Female Condom. Displaying page 1 of 138.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-021193-11 Sponsor Protocol Number: HT-07 Start Date*: 2010-09-14
    Sponsor Name:Helperby Thearapeutics Ltd
    Full Title: A randomised, open-labelled, multiple dose study of HT61 formulations applied to the anterior nares plus chlorhexidine body and hair washes in subjects with nasal carriage of Staphylococcus aureus
    Medical condition: Nasal carriage of Staphylococcus aureus (including MRSA)
    Disease: Version SOC Term Classification Code Term Level
    13 10067914 Staphylococcal colonisation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017398-39 Sponsor Protocol Number: HT-04 Start Date*: 2010-02-02
    Sponsor Name:Helperby Thearapeutics Ltd
    Full Title: Randomised double-blind, vehicle controlled dosing frequency study of HT61 1% gel applied to the anterior nares plus chlorhexidine body and hair washes in subjects with nasal carriage of Staphyloco...
    Medical condition: Nasal carriage of Staphylococcus aures (including MRSA)
    Disease: Version SOC Term Classification Code Term Level
    12 10067910 Staphylococcal colonisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017647-34 Sponsor Protocol Number: ANTIRESDEV Start Date*: 2010-03-29
    Sponsor Name:Helperby Therapeutics
    Full Title: Effect of minocycline and amoxicillin administration on the prevalence of antibiotic resistant bacteria and on the indigenous oral, faecal, cutaneous and nasal microbiotas.
    Medical condition: Amoxicillin and Minocycline are marketed antibiotic to fight bacterial infections.
    Disease: Version SOC Term Classification Code Term Level
    12 10002737 Antibiotic Resistant Strain SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021125-12 Sponsor Protocol Number: TMC207TBC3001 Start Date*: 2011-09-16
    Sponsor Name:Janssen Infectious Diseases BVBA
    Full Title: Early access of TMC207 in combination with other anti-tuberculosis (TB) drugs in subjects with extensively drug resistant (XDR) or pre-XDR pulmonary TB
    Medical condition: Tuberculosis (TB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019203-31 Sponsor Protocol Number: D1220C00001 Start Date*: 2011-02-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine...
    Medical condition: Acute Migraine Headache in Adolescents
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066635 Acute migraine LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) LV (Completed) HU (Completed) PL (Completed) FI (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-010763-17 Sponsor Protocol Number: EBSBTXA09 Start Date*: 2009-05-26
    Sponsor Name:Sophiahemmet
    Full Title: Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia congenita-a double-blind placebo-controlled phase II proof of concept study
    Medical condition: Epidermolysis Bullosa Simplex and Pachyonychia Congenita
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020832-20 Sponsor Protocol Number: P06356 Start Date*: 2010-08-13
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation - for Global trials
    Full Title: An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356)
    Medical condition: This study is going to be conducted in heathy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002518-11 Sponsor Protocol Number: 8835-004 Start Date*: 2014-01-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES ME...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) GR (Completed) HR (Completed) SK (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-002844-93 Sponsor Protocol Number: 6002-INT-001 Start Date*: 2005-02-08
    Sponsor Name:Kyowa Hakko U.K. Limited
    Full Title: A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Lev...
    Medical condition: Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) GB (Completed) EE (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005569-12 Sponsor Protocol Number: CSTI571E2203 Start Date*: 2006-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial...
    Medical condition: pulmonary arterial hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002414-39 Sponsor Protocol Number: MK-3102-018 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) DE (Completed) NO (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) FI (Completed) DK (Prematurely Ended) IT (Completed) BE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005586-13 Sponsor Protocol Number: AB12009 Start Date*: 2013-08-19
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with s...
    Medical condition: Patients with severe COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SK (Prohibited by CA) GR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-003618-41 Sponsor Protocol Number: MOM-M281-005 Start Date*: 2019-06-05
    Sponsor Name:Momenta Pharmaceuticals, Inc.
    Full Title: An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003167-54 Sponsor Protocol Number: EIG-LNF-011 Start Date*: 2019-06-24
    Sponsor Name:Eiger BioPharmaceuticals, Inc.
    Full Title: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared...
    Medical condition: The proposed indication for lonafarnib coadministered with ritonavir is for the treatment of chronic HDV infection. Approximately 5% of HBV-infected individuals are infected with HDV worldwide. Ch...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BG (Completed) GR (Completed) ES (Ongoing) SE (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019991-55 Sponsor Protocol Number: CC-10004-PSOR-008 Start Date*: 2011-01-25
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis
    Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023034-23 Sponsor Protocol Number: B0151003 Start Date*: 2011-06-03
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH CROHN’S DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (ANDANTE)
    Medical condition: Crohn's Disease (active moderate to severe)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) HU (Completed) GB (Completed) GR (Completed) DK (Completed) DE (Completed) BE (Completed) IT (Completed) CZ (Completed) AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002176-39 Sponsor Protocol Number: V3002401 Start Date*: 2022-02-07
    Sponsor Name:Veru Inc.
    Full Title: ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with A...
    Medical condition: (AR+)/estrogen receptor positive(ER+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011626-34 Sponsor Protocol Number: CAIN457B2201 Start Date*: 2009-10-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 2...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-004825-26 Sponsor Protocol Number: G200712 Start Date*: 2013-01-25
    Sponsor Name:GTx, Inc.
    Full Title: Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with castration resistant prostate cancer maintained on and...
    Medical condition: Assessments of serum total testosterone, serum free testosterone, serum SHGB and serum PSA concentrations will be made. Bone turnover markers and the incidence and frequency of hot flashes will be ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018386-32 Sponsor Protocol Number: CC-10004-PSA-003 Start Date*: 2010-12-27
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) GB (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA